A Phase 1/2, Open-Label Study of Nivolumab (BMS-936558) in Chinese Subjects With Previously Treated Advanced or Recurrent Solid Tumors (CheckMate 077: CHECKpoint Pathway and nivoluMAb Clinical Trial Evaluation 077)

Trial Profile

A Phase 1/2, Open-Label Study of Nivolumab (BMS-936558) in Chinese Subjects With Previously Treated Advanced or Recurrent Solid Tumors (CheckMate 077: CHECKpoint Pathway and nivoluMAb Clinical Trial Evaluation 077)

Recruiting
Phase of Trial: Phase I/II

Latest Information Update: 10 Jun 2017

At a glance

  • Drugs Nivolumab (Primary)
  • Indications Solid tumours
  • Focus Adverse reactions
  • Acronyms CheckMate 077
  • Sponsors Bristol-Myers Squibb
  • Most Recent Events

    • 01 Jun 2017 Planned End Date changed from 1 Apr 2019 to 30 Jul 2019.
    • 16 Feb 2017 Planned End Date changed from 11 Apr 2019 to 1 Apr 2019.
    • 16 Feb 2017 Planned primary completion date changed from 1 Jul 2018 to 1 Apr 2019.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top